Skip to main content
. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436

Table 1. Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support.*.

Characteristic Treatment Assignment Respiratory Support Received
at Randomization
Dexamethasone
(N=2104)
Usual Care
(N=4321)
No Receipt of Oxygen
(N=1535)
Oxygen
Only
(N=3883)
Invasive Mechanical Ventilation
(N=1007)
Age
Mean — yr 66.9±15.4 65.8±15.8 69.4±17.5 66.7±15.3 59.1±11.4
Distribution — no. (%)
<70 yr 1141 (54) 2504 (58) 659 (43) 2148 (55) 838 (83)
70 to 79 yr 469 (22) 859 (20) 338 (22) 837 (22) 153 (15)
≥80 yr 494 (23) 958 (22) 538 (35) 898 (23) 16 (2)
Sex — no. (%)
Male 1338 (64) 2749 (64) 891 (58) 2462 (63) 734 (73)
Female 766 (36) 1572 (36) 644 (42) 1421 (37) 273 (27)
Median no. of days since symptom onset (IQR)§ 8 (5–13) 9 (5–13) 6 (3–10) 9 (5–12) 13 (8–18)
Median no. of days since hospitalization (IQR) 2 (1–5) 2 (1–5) 2 (1–6) 2 (1–4) 5 (3–9)
Respiratory support received — no. (%)
No oxygen 501 (24) 1034 (24) 1535 (100) NA NA
Oxygen only 1279 (61) 2604 (60) NA 3883 (100) NA
Invasive mechanical ventilation 324 (15) 683 (16) NA NA 1007 (100)
Previous coexisting disease
Any 1174 (56) 2417 (56) 911 (59) 2175 (56) 505 (50)
Diabetes 521 (25) 1025 (24) 342 (22) 950 (24) 254 (25)
Heart disease 586 (28) 1171 (27) 519 (34) 1074 (28) 164 (16)
Chronic lung disease 415 (20) 931 (22) 351 (23) 883 (23) 112 (11)
Tuberculosis 6 (<1) 19 (<1) 8 (1) 11 (<1) 6 (1)
HIV infection 12 (1) 20 (<1) 5 (<1) 21 (1) 6 (1)
Severe liver disease 37 (2) 82 (2) 32 (2) 72 (2) 15 (1)
Severe kidney impairment 166 (8) 358 (8) 119 (8) 253 (7) 152 (15)
SARS-CoV-2 test result
Positive 1850 (88) 3848 (89) 1333 (87) 3416 (88) 949 (94)
Negative 247 (12) 453 (10) 193 (13) 452 (12) 55 (5)
Test result not yet known 7 (<1) 20 (<1) 9 (1) 15 (<1) 3 (<1)
*

Plus–minus values are means ±SD. HIV denotes human immunodeficiency virus, IQR interquartile range, NA not applicable, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.

There was a significant (P=0.01) difference in the mean age between patients in the dexamethasone group and those in the usual care group, but there were no significant differences between the groups in any other baseline characteristic.

Included in this category were 6 pregnant women.

§

Data regarding the number of days since symptom onset were missing for 4 patients in the dexamethasone group and 13 patients in the usual care group; these patients were excluded from estimates of the median number of days since onset.

Severe liver disease was defined as requiring ongoing specialist care.

Severe kidney impairment was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m2.